Preparation of membrane pellet Tumour specimens removed from -70'C were allowed to thaw on ice, while those from sucrose/glycerol were re-hydrated in homogenising buffer (see below). The tumour specimen was dried with tissue paper to remove any excess water or buffer. Specimens were washed in ice cold saline. The tumour was bisected and two separate samples of tumour were cut (2-3 mm minimum) from either half, one piece placed in formal saline for pathological analysis and the other in sucrose/glycerol buffer for later immunohistochemical analysis (to be reported later). The remainder of the tumour was used for the biochemical assay. Fresh homogenising buffer was prepared (20 mM Hepes, 2 mM EDTA, 0.5 mM PMSF to pH 7.4). Tumour sections were then cut into small 1 mm blocks and weighed (usually 1 gram), then placed in a centrifuge tube to which was added 5 ml g-' (wet weight) of ice cold homogenising buffer. Tumour was homogenised on ice with an ultra turrax (Janke and Kunkel) with 2 x 15 s bursts at maximum speed but allowing the homogenate to cool between bursts. The homogenate was centrifuged at 1,000 g for 10 min. The resulting supernatant was centrifuged at 12,000 g for 1 h. The nuclear pellet was resuspended in homogenising buffer and stored at -20C until required for DNA analysis (Modified Burton). The pellet from the high speed spin was resuspended in 1-2 ml of radioimmunoassay buffer (RIA buffer: 0.2 M Na2HPO4, 0.2 M NaH2PO4, 0.1% sodium azide, 0.15 M sodium chloride, 0.1 M EDTA and 0.5% bovine serum albumin to pH 7.4) depending on the initial wet weight (1 ml 500 mg-') and stored at -20C in 1.5 ml polystyrene tubes (Eppendorfs). Prior to storage each suspension was submitted to glass teflon homogenisation to ensure an even suspension. 
Epidermal growth factor (EGF) interaction with EGFR results in growth of some epithelial cancer cells in vitro and EGFR has been found in both normal and malignant tissue samples. Hoffmann et al. (1984) found EGFR in normal human endometrium, while Korc et al. (1986) found the receptor in human endometrial carcinoma. Battaglia et al. (1989) found that 18 of 24 (75%) ovarian tumours expressed EGFR. Bauknecht et al. (1989) reported that 64 of 151 (45%) ovarian cancers displayed the receptor. Others such as Neal et al. (1990) found EGFR in 48% of bladder tumours. A significant amount of work has been done with EGFR expression in breast cancer initially by Fitzpatrick et al. (1984) , more recently by Sainsbury et al. (1985 and and Nicholson et al. (1988) . In fact Sainsbury et al. (1987) found that both EGFR and oestrogen receptor (ER) status could predict prognosis. Patients who were EGFR+ /ER-had the worst prognosis and those who were EGFR-/ER + the best.
To further investigate the role of EGFR in ovarian neoplasia we have examined 150 consecutive patients with ovarian cancer who had at least one sample analysed by a biochemical assay.
Materials and methods
Patient selection, collection and storage of tumour specimens Patients were recruited prospectively and included any patient with ovarian cancer. Tumour was either collected fresh, snap frozen in liquid nitrogen and later stored at -70°C or transported on ice in sucrose/glycerol buffer (Crawford et al., 1984) and stored at -20'C until assayed. Occasionally, not only one ovary but both ovaries and omentum were analysed from the same patient. Experiments on placental tissue over time and storage conditions (liquid nitrogen and -70°C or sucrose/glycerol buffer and -20C) showed that similar results were obtained (Owens, MD thesis, 1990 ).
Preparation of membrane pellet Tumour specimens removed from -70'C were allowed to thaw on ice, while those from sucrose/glycerol were re-hydrated in homogenising buffer (see below). The tumour specimen was dried with tissue paper to remove any excess water or buffer. Specimens were washed in ice cold saline. The tumour was bisected and two separate samples of tumour were cut (2-3 mm minimum) from either half, one piece placed in formal saline for pathological analysis and the other in sucrose/glycerol buffer for later immunohistochemical analysis (to be reported later). The remainder of the tumour was used for the biochemical assay. Fresh homogenising buffer was prepared (20 mM Hepes, 2 mM EDTA, 0.5 mM PMSF to pH 7.4). Tumour sections were then cut into small 1 mm blocks and weighed (usually 1 gram), then placed in a centrifuge tube to which was added 5 ml g-' (wet weight) of ice cold homogenising buffer. Tumour was homogenised on ice with an ultra turrax (Janke and Kunkel) with 2 x 15 s bursts at maximum speed but allowing the homogenate to cool between bursts. The homogenate was centrifuged at 1,000 g for 10 min. The resulting supernatant was centrifuged at 12,000 g for 1 h. The nuclear pellet was resuspended in homogenising buffer and stored at -20C until required for DNA analysis (Modified Burton). The pellet from the high speed spin was resuspended in 1-2 ml of radioimmunoassay buffer (RIA buffer: 0.2 M Na2HPO4, 0.2 M NaH2PO4, 0.1% sodium azide, 0.15 M sodium chloride, 0.1 M EDTA and 0.5% bovine serum albumin to pH 7.4) depending on the initial wet weight (1 ml 500 mg-') and stored at -20C in 1.5 ml polystyrene tubes (Eppendorfs). Prior to storage each suspension was submitted to glass teflon homogenisation to ensure an even suspension. 40 ,000 g in a refrigerated unit at 4'C (Sarstedt) for 10 min.
The supernatant was removed with a pasteur attached to a water pump leaving a pellet which was counted on a gamma counter (60% efficiency). Data were analysed using an 'in house' programme (adapted from Leake et al., 1987) . The programme corrected for non-specific binding using the three competition values (tubes [13] [14] [15] Object of study There were three main objectives in this study. Firstly to document the incidence of EGFR in a group of 150 consecutive patients with ovarian cancer both by single point screen and full Scatchard analysis. Secondly to determine if there was any statistical difference between degree of differentiation of the tumour and the presence of the EGFR and finally to see if there was a difference between stage of disease and presence of the EGFR.
Statistical analysis Chi square testing was used for statistical analysis.
Results
Placental tissue experiments Preliminary experiments, using a human placental membrane fraction, were performed to find out the effect of time on the percentage mEGF bound to placental membrane at 4°C, room temperature and 37°C. Figure 1 shows that maximum 02 0L
binding was achieved at room temperature at 120 min. This formed the basis of the subsequent single point screens and full Scatchard analysis. Figure 2 shows (Serov et al., 1973) into five main categories which comprised serous, endometrioid, mucinous, clear cell and undifferentiated sub-types of common epithelial tumours. A further 18 patients were analysed separately. All patients were staged in accordance with the revised FIGO staging for ovarian cancer (Shepherd, 1989) . Stage 1 and 2 were subdivided into a, b and c. However, it was not possible to subdivide stage 3 into its various sub stages.
Results of tumour specimens The results are divided into three tables. Table I illustrates the patient characteristics for the major types of common epithelial tumour. The majority of samples fall into the serous group. Sample number is greater than patient number because sometimes tumour was recovered from both ovaries and omentum. The majority of patients were stage 3 and 4. Certainly in the serous group 77.5% of patients presented with stage 3 or 4 disease. Because it is too early to analyse survival (follow up ranges from 1 to 19 months) it was felt unnecessary to subdivide stage 1 and 2 at present. Table II compares the presence of EGFR in the various groups. EGFR presence varied between 36.4% in the mucinous group and 47.4% in the undifferentiated group. The low affinity receptor was present in 31 of 73 positive samples (42.5%), while the high affinity receptor was present in 26 of 73 (35.6%) and 16 of 73 samples (21.9%) had both high and low affinity receptors. Table Illa gives the various ranges and median values for the serous, endometrioid and mucinous group with regard to low, high and low plus high affinity receptor groups. Table  IlIb gives all positive single point screens actually have receptors present on full Scatchard analysis. Indeed, less than 70% of positive single point screens contained receptor on full Scatchard analysis using at least five separate data points and a regression coefficient > 0.8. We examined a number of negative single point screen samples and were unable to demonstrate the receptor in any case. Discordant results occurred in up to 25% of samples when more than one specimen from the same patient was analysed. This is probably related to the heterogeneity of ovarian tumours. Battaglia et al. (1989) interestingly found that 18 of 24 (75%) primary ovarian samples expressed detectable levels of EGFR. They only used a range of Scatchard points between 0.4-2.6 nm and this range of concentration would not necessarily detect all possible high affinity components nor all low affinity components. It is thus puzzling that Battaglia et al.
(1989) had so many positive results. In their study metastatic deposits had a higher concentration of EGFR compared to primary sites and a higher median EGFR level in poorly differentiated than in moderately and well differentiated groups. We were unable to find any significant difference between degree of differentiation of the tumour and the total receptor concentration or the Kd, nor between stage of the disease and the presence of the receptor.
The current data do not explain the significance of why some tumours have high, some low and some both high plus low affinity binding sites. Various mechanisms have been proposed for the presence of two binding sites of differing affinity. Some sites may have been occupied by endogenous growth factors and undergone autophosphorylation and down regulation. Dimerisation has been proposed by Schlessinger (1988) in that monomeric receptors are in equilibrium with oligomeric receptors. Secondly it has been shown that there is an interaction between protein kinase C (PKC) and the EGFR such that there is a decrease in affinity for EGF and that high levels of PKC are associated with hormone independent tumours (Wyss et al., 1987) . Thirdly it is possible that another growth factor is interacting with PKC, modulating EGFR (Roos et al., 1986) . The observed discordance in individual patients may be due to different populations of tumour cells in different sections which have been used for biochemical assay just as there may be variations in histology between sections.
It has been noted by Bauknecht et al. (1988) that a response to chemotherapy occurred in 50% of EGFR positive cancers with a mean survival time of 28 months while the response rate in EGFR negative ovarian cancers was 12% with a mean survival of 16 months. Our results have not yet been analysed in this way as it was felt that the time interval was not sufficiently long.
Currently we are therefore unable to confirm whether the presence of the receptor (EGFR) alone has prognostic significance and if so does high, low, or high plus low affinity receptors have any independent functional role. It may be that stage of the disease, degree of differentiation along with bulk residual disease and monitoring of CA125 offer the best prognostic indices. Secondly follow up analysis should indicate whether the presence or absence of the receptor predict a better response to chemotherapy. Finally, the significance of discordant results require further investigation in relation to overall tumour biology. 
